{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:14:15Z","timestamp":1753881255767,"version":"3.41.2"},"reference-count":40,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100015311","name":"Novartis AG | Novartis Institutes for BioMedical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015311","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2022,12,20]]},"abstract":"<jats:p>\n            CUO246, a novel DNA gyrase\/topoisomerase IV inhibitor, is active\n            <jats:italic>in vitro<\/jats:italic>\n            against a broad range of Gram-positive, fastidious Gram-negative, and atypical bacterial pathogens and retains activity against quinolone-resistant strains in circulation. The frequency of selection for single step mutants of wild-type\n            <jats:named-content content-type=\"genus-species\">S. aureus<\/jats:named-content>\n            with reduced susceptibility to CUO246 was &lt;4.64\u2009\u00d7\u200910\n            <jats:sup>\u22129<\/jats:sup>\n            at 4\u00d7 and 8\u00d7 MIC and remained low when using an isogenic QRDR mutant (&lt;5.24\u2009\u00d7\u200910\n            <jats:sup>\u22129<\/jats:sup>\n            at 4\u00d7 and 8\u00d7 MIC).\n          <\/jats:p>","DOI":"10.1128\/aac.00921-22","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T14:01:04Z","timestamp":1669816864000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":2,"title":["<i>In Vitro<\/i>\n            and\n            <i>In Vivo<\/i>\n            Properties of CUO246, a Novel Bacterial DNA Gyrase\/Topoisomerase IV Inhibitor"],"prefix":"10.1128","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8139-8855","authenticated-orcid":true,"given":"Johanne","family":"Blais","sequence":"first","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Emeryville, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9858-9818","authenticated-orcid":true,"given":"Charles R.","family":"Dean","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Emeryville, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Lapointe","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Emeryville, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer A.","family":"Leeds","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Emeryville, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia","family":"Ma","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Emeryville, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Morris","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Emeryville, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz E.","family":"Moser","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Emeryville, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin S.","family":"Osborne","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Emeryville, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine R.","family":"Prosen","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Emeryville, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daryl","family":"Richie","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Emeryville, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin","family":"Skepper","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Emeryville, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Thompson","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Emeryville, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Vo","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Emeryville, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Yue","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Emeryville, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexey","family":"Rivkin","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Emeryville, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm01240a021"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2005.01131.x"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrm831"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-011-3557-z"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.70.1.369"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.5.1856-1864.2004"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/mutage\/gep035"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02794-15"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02803-15"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.27.2.335-336.1989"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/668770"},{"key":"e_1_3_3_13_2","volume-title":"Antibiotic resistance threats in the United States","author":"Centers for Disease Control and Prevention (CDC)","year":"2013","unstructured":"Centers for Disease Control and Prevention (CDC). 2013. Antibiotic resistance threats in the United States."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1586\/eri.13.12"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/595011"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05658-11"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01260-07"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2014.03.2737"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2014.935470"},{"key":"e_1_3_3_20_2","first-page":"332","article-title":"Update to CDC\u2019s sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections","volume":"56","author":"Centers for Disease Control and Prevention (CDC)","year":"2007","unstructured":"Centers for Disease Control and Prevention (CDC). 2007. Update to CDC\u2019s sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. Morbidity and Mortality Wkly Report 56:332\u2013336.","journal-title":"Morbidity and Mortality Wkly Report"},{"key":"e_1_3_3_21_2","first-page":"581","article-title":"Update to CDC\u2019s sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections","volume":"61","author":"Centers for Disease Control and Prevention (CDC)","year":"2012","unstructured":"Centers for Disease Control and Prevention (CDC). 2012. Update to CDC\u2019s sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. Morbidity and Mortality Wkly Report 61:581\u2013604.","journal-title":"Morbidity and Mortality Wkly Report"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-010-0299-5"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0966-842X(98)01311-0"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm060505l"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01666-10"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep11827"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw061"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature09197"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00347"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00375"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01016-15"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw288"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.5.4.387"},{"key":"e_1_3_3_34_2","volume-title":"Methods for dilution susceptibility tests for bacteria that grow aerobically; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute. 2015. Methods for dilution susceptibility tests for bacteria that grow aerobically; approved standard, 10th ed. CLSI document M07-A10. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"10"},{"key":"e_1_3_3_35_2","volume-title":"Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard, 8th ed. CLSI document M11-A8. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"8"},{"key":"e_1_3_3_36_2","volume-title":"Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic Actinomycetes; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2011","unstructured":"Clinical and Laboratory Standards Institute. 2011. Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic Actinomycetes; approved standard, 2nd ed. CLSI document M24-A2. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"2"},{"key":"e_1_3_3_37_2","volume-title":"Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria; approved guideline","author":"Clinical and Laboratory Standards Institute","year":"2016","unstructured":"Clinical and Laboratory Standards Institute. 2016. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria; approved guideline, 3rd ed. CLSI document M45-A3. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"3"},{"key":"e_1_3_3_38_2","volume-title":"Methods for determining bactericidal activity of antimicrobial agents; approved guideline","author":"Clinical and Laboratory Standards Institute","year":"2009","unstructured":"Clinical and Laboratory Standards Institute. 2009. Methods for determining bactericidal activity of antimicrobial agents; approved guideline. CLSI document M26-A. Clinical Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02100-16"},{"key":"e_1_3_3_40_2","volume-title":"Performance standards for antimicrobial susceptibility testing. Approved standard M100","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Performance standards for antimicrobial susceptibility testing. Approved standard M100, 28th ed. Informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA, USA.","edition":"28"},{"key":"e_1_3_3_41_2","unstructured":"Wyeth Pharmaceuticals Inc. 2016. Tygacil: highlights of prescribing information. Wyeth Pharmaceuticals Inc. Philadelphia PA. http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=491."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00921-22","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00921-22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T14:09:04Z","timestamp":1671545344000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00921-22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,20]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12,20]]}},"alternative-id":["10.1128\/aac.00921-22"],"URL":"https:\/\/doi.org\/10.1128\/aac.00921-22","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"type":"print","value":"0066-4804"},{"type":"electronic","value":"1098-6596"}],"subject":[],"published":{"date-parts":[[2022,12,20]]},"assertion":[{"value":"2022-07-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00921-22"}}